AR036154A1 - Anticuerpos especificos de cd44v6. - Google Patents
Anticuerpos especificos de cd44v6.Info
- Publication number
- AR036154A1 AR036154A1 ARP020101830A ARP020101830A AR036154A1 AR 036154 A1 AR036154 A1 AR 036154A1 AR P020101830 A ARP020101830 A AR P020101830A AR P020101830 A ARP020101830 A AR P020101830A AR 036154 A1 AR036154 A1 AR 036154A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibody
- variants
- seq
- fragments
- variable region
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2884—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Anticuerpos con una secuencia especificada, que son específicos de un epítopo que está codificado por el exón v6 variante del gen CD44 y a derivados de dicho anticuerpo. También proporciona moléculas de ácido nucleico que codifican dichas proteínas anticuerpo. Además concierne a métodos para producir dichas proteínas anticuerpo. También proporciona composiciones farmacéuticas que comprenden dichas proteínas anticuerpo. Además está relacionado con la aplicación en la fabricación de un medicamento para el tratamiento del cáncer. Reivindicación 1: Una molécula de anticuerpo que comprende una región variable de la cadena pesada caracterizada por la secuencia de aminoácidos definida en la SEQ ID No. 1, o uno de sus fragmentos, variantes alélicas, variantes funcionales, variantes de glicosilación, moléculas de fusión o derivados químicos. Reivindicación 3: Una molécula de anticuerpo que comprende una región variable de la cadena ligera caracterizada por la secuencia de aminoácidos definida en la SEQ ID No. 2, o uno de sus fragmentos, variantes alélicas, variantes funcionales, variantes de glicosilación, moléculas de fusión o derivados químicos. Reivindicación 39: La proteína anticuerpo de la reivindicación 38, en la que dicho agente terapéutico es un agente terapéutico seleccionado entre el grupo constituido por radioisótopos, toxinas, toxoides, agentes inflamatorios y agentes quimioterapéuticos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01112237 | 2001-05-18 | ||
| US32514701P | 2001-09-26 | 2001-09-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR036154A1 true AR036154A1 (es) | 2004-08-18 |
Family
ID=33442672
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020101830A AR036154A1 (es) | 2001-05-18 | 2002-05-17 | Anticuerpos especificos de cd44v6. |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP1397387A1 (es) |
| JP (1) | JP2005504517A (es) |
| CN (1) | CN1541226A (es) |
| AR (1) | AR036154A1 (es) |
| BR (1) | BR0210905A (es) |
| CA (1) | CA2443437A1 (es) |
| CZ (1) | CZ20033476A3 (es) |
| EA (1) | EA200301169A1 (es) |
| EC (1) | ECSP034838A (es) |
| EE (1) | EE200300569A (es) |
| HU (1) | HUP0400030A3 (es) |
| MX (1) | MXPA03010523A (es) |
| PE (1) | PE20021098A1 (es) |
| PL (1) | PL365735A1 (es) |
| SK (1) | SK15592003A3 (es) |
| WO (1) | WO2002094879A1 (es) |
| YU (1) | YU91403A (es) |
| ZA (1) | ZA200307365B (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8071072B2 (en) | 1999-10-08 | 2011-12-06 | Hoffmann-La Roche Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
| US7189397B2 (en) * | 1999-10-08 | 2007-03-13 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
| US8048416B2 (en) | 1999-10-08 | 2011-11-01 | Hoffmann-La Roche Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
| US20050100542A1 (en) | 1999-10-08 | 2005-05-12 | Young David S. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
| US7947496B2 (en) | 1999-10-08 | 2011-05-24 | Hoffmann-La Roche Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
| US7084257B2 (en) | 2001-10-05 | 2006-08-01 | Amgen Inc. | Fully human antibody Fab fragments with human interferon-gamma neutralizing activity |
| US20050232919A1 (en) | 2004-02-12 | 2005-10-20 | Morphotek, Inc. | Monoclonal antibodies that specifically block biological activity of a tumor antigen |
| JP4949373B2 (ja) | 2005-03-10 | 2012-06-06 | モルフォテック、インク． | 抗メソテリン抗体 |
| EP1879922A2 (en) | 2005-04-22 | 2008-01-23 | Morphotek, Inc. | Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells |
| HUE038445T2 (hu) * | 2007-06-13 | 2018-10-29 | Zymogenetics Inc | TACI-IG fúziós fehérje, például atacicept alkalmazása lupusz eritomatózusz kezelésére szolgáló gyógyszer elõállítására |
| EP2009028A1 (en) * | 2007-06-27 | 2008-12-31 | Monoclonal Antibodies Therapeutics | Combination of a conventional anti-cancer treatment with anti-CD44 antibody administration for treating solid tumors |
| JP5763105B2 (ja) | 2010-02-04 | 2015-08-12 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 頭頸部扁平上皮癌の治療に使用されるｃｄ４４に対するモノクローナル抗体 |
| CN102337298B (zh) * | 2011-08-19 | 2013-11-06 | 黄开红 | 一种输送siRNA的免疫纳米载体及其制备方法和应用 |
| EP2788024A1 (en) | 2011-12-06 | 2014-10-15 | F.Hoffmann-La Roche Ag | Antibody formulation |
| WO2017215637A1 (zh) * | 2016-06-15 | 2017-12-21 | 李翀 | 一种人子宫内膜癌的标志物、抗体及其应用 |
| CN107556388A (zh) * | 2016-06-30 | 2018-01-09 | 中国科学院深圳先进技术研究院 | 抗CD44v6和CD3特异性双靶向抗体、含该双靶向抗体表达盒的微环DNA及应用 |
| EP4114860A1 (en) * | 2020-03-06 | 2023-01-11 | Go Therapeutics, Inc. | Anti-glyco-cd44 antibodies and their uses |
| JP2024512324A (ja) * | 2021-03-05 | 2024-03-19 | ジーオー セラピューティクス，インコーポレイテッド | 抗グリコｃｄ４４抗体およびその使用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IL162181A (en) * | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| EP0438310A1 (en) * | 1990-01-19 | 1991-07-24 | Merck & Co. Inc. | Method for producing recombinant immunoglobuline |
| GB9020282D0 (en) * | 1990-09-17 | 1990-10-31 | Gorman Scott D | Altered antibodies and their preparation |
| EP0672130A1 (en) * | 1992-11-20 | 1995-09-20 | Isis Innovation Limited | Peptide corresponding to cd44 exon 6, antibodies specific for said peptide and use of these antibodies for diagnosis of tumors |
| UA58482C2 (uk) * | 1994-06-08 | 2003-08-15 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Моноклональне антитіло vff-18 проти сd44v6 і його фрагменти |
| UY24389A1 (es) * | 1995-12-06 | 2001-10-25 | Karlsruhe Forschzent | Composición farmacéutica para el tratamiento de carcinoma de epitelio plano |
-
2002
- 2002-05-17 EE EEP200300569A patent/EE200300569A/xx unknown
- 2002-05-17 HU HU0400030A patent/HUP0400030A3/hu unknown
- 2002-05-17 SK SK1559-2003A patent/SK15592003A3/sk not_active Application Discontinuation
- 2002-05-17 JP JP2002592353A patent/JP2005504517A/ja active Pending
- 2002-05-17 CA CA002443437A patent/CA2443437A1/en not_active Abandoned
- 2002-05-17 AR ARP020101830A patent/AR036154A1/es unknown
- 2002-05-17 CN CNA028101561A patent/CN1541226A/zh active Pending
- 2002-05-17 YU YU91403A patent/YU91403A/sh unknown
- 2002-05-17 EP EP02735364A patent/EP1397387A1/en not_active Ceased
- 2002-05-17 PE PE2002000422A patent/PE20021098A1/es not_active Application Discontinuation
- 2002-05-17 CZ CZ20033476A patent/CZ20033476A3/cs unknown
- 2002-05-17 EA EA200301169A patent/EA200301169A1/ru unknown
- 2002-05-17 PL PL02365735A patent/PL365735A1/xx not_active Application Discontinuation
- 2002-05-17 BR BR0210905-0A patent/BR0210905A/pt not_active IP Right Cessation
- 2002-05-17 MX MXPA03010523A patent/MXPA03010523A/es unknown
- 2002-05-17 WO PCT/EP2002/005467 patent/WO2002094879A1/en not_active Ceased
-
2003
- 2003-09-22 ZA ZA200307365A patent/ZA200307365B/xx unknown
- 2003-11-10 EC EC2003004838A patent/ECSP034838A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA03010523A (es) | 2004-07-01 |
| BR0210905A (pt) | 2004-06-08 |
| HUP0400030A2 (hu) | 2004-04-28 |
| ZA200307365B (en) | 2004-05-10 |
| PE20021098A1 (es) | 2003-02-11 |
| ECSP034838A (es) | 2003-12-24 |
| CZ20033476A3 (cs) | 2004-05-12 |
| SK15592003A3 (sk) | 2004-06-08 |
| WO2002094879A1 (en) | 2002-11-28 |
| PL365735A1 (en) | 2005-01-10 |
| CN1541226A (zh) | 2004-10-27 |
| EE200300569A (et) | 2004-04-15 |
| EA200301169A1 (ru) | 2004-06-24 |
| CA2443437A1 (en) | 2002-11-28 |
| HUP0400030A3 (en) | 2006-02-28 |
| JP2005504517A (ja) | 2005-02-17 |
| EP1397387A1 (en) | 2004-03-17 |
| YU91403A (sh) | 2006-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR036154A1 (es) | Anticuerpos especificos de cd44v6. | |
| ES2699753T3 (es) | Mimótopos peptídicos de claudina 18.2 y sus usos | |
| Wentzel et al. | Sequence requirements of the GPNG β-turn of the Ecballium elaterium trypsin inhibitor II explored by combinatorial library screening | |
| ECSP044978A (es) | ANTICUERPOS HUMANOS ANTAGONISTAS CONTRA hTNFSF13b | |
| ATE510011T1 (de) | Neue pilzproteine und diese codierende nukleinsäuren | |
| ECSP14011269A (es) | Formulaciones de anticuerpos y proteínas de alta concentración | |
| AR047717A1 (es) | Anticuerpos dirigidos a c-met | |
| WO2002083171A3 (en) | Cancer treatment by using fap-alpha specific antibodies | |
| ATE382053T1 (de) | System zur antikörperexpression und- synthese | |
| AR045056A1 (es) | Anticuerpos anti-ngf humanos neutralizantes como inhibidores selectivos de la via de ngf | |
| AR071510A1 (es) | Anticuerpos anti- factor d humanizados y sus usos | |
| BRPI0411112A (pt) | proteìna de fusão heteróloga, polinucleotìdeo, vetor, célula hospedeira, processo para produzir uma proteìna de fusão heteróloga, método para tratar um paciente, e, uso de proteìna de fusão heteróloga | |
| CY1110848T1 (el) | Αντισωμα αντι ανθρωπου νοgo α kai h φαρμακευτικη του χρηση | |
| CY1112334T1 (el) | Ομολογα πολυπεπτιδια il-17 και θεραπευτικες χρησεις αυτων | |
| SG170080A1 (en) | Human monoclonal antibodies to o8e | |
| AR030236A1 (es) | Moléculas similares a il-17 y usos de las mismas | |
| ATE209680T1 (de) | Isolierte nukleinsäuremoleküle, peptide die mit hla-a2 moleküle (mhc) komplexe bilden, sowie deren verwendungen | |
| PE20240086A1 (es) | Anticuerpos anti-cd122 y usos de estos | |
| JP2005504517A5 (es) | ||
| EA200701947A1 (ru) | Легкая фармацевтическая вода, терапевтические композиции, ее содержащие, способы их производства и применения | |
| BRPI0407031A (pt) | Composições e métodos para tratamento de câncer empregando igsf9 e liv-1 | |
| MXPA05011085A (es) | Composiciones y metodos relacionados a stop-1. | |
| EA200600042A1 (ru) | Способы образования дисульфидных связей и гликозилирования белков и реагенты, применяемые в этих способах | |
| BR0113099A (pt) | Gene e proteìna relacionados com esquizofrenia | |
| AR004360A1 (es) | Composiciones farmaceuticas para la terapia de carcinomas del epitelio plano y un agente para ser empleado en estas composicines farmaceuticas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |